File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1034/j.1600-051X.2002.290611.x
- Scopus: eid_2-s2.0-0036598367
- PMID: 12296782
- WOS: WOS:000178184000011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Local antimicrobial therapy after initial periodontal treatment: A randomized clinical trial comparing three biodegradable sustained release polymers
Title | Local antimicrobial therapy after initial periodontal treatment: A randomized clinical trial comparing three biodegradable sustained release polymers |
---|---|
Authors | |
Keywords | Biodegradable drug delivery systems Microbiological effects Periodontal disease Periodontal therapy Randomized clinical trial (RCT) |
Issue Date | 2002 |
Publisher | Blackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CPE |
Citation | Journal Of Clinical Periodontology, 2002, v. 29 n. 6, p. 540-550 How to Cite? |
Abstract | Aim: The aim of this single-blind, randomized, parallel-designed clinical trial (RCT) was to evaluate the clinical and microbiological effects of three sustained-release biodegradable polymers delivered into periodontal pockets following initial periodontal therapy. Methods: Forty-seven patients (28 females and 19 males) with a mean age of 51 years (range 29-71) underwent a periodontal examination at baseline (i.e. Week 0) and after 18 weeks. This included the assessment of the Plaque Index (PlI), Bleeding on Probing (BOP), Pocket Probing Depths (PPD) and Probing Attachment Levels (PAL) at six sites per tooth. Two to 4 months prior to baseline, all subjects had received initial periodontal therapy including motivation, instruction in oral hygiene practices and full-mouth scaling and root planing. At the treatment appointment (i.e. Week 2), the patients were randomly assigned to receive either Atridox™, Elyzol® Dental Gel or PerioChip® at all residual periodontal pockets with a probing depth ≥ 5 mm and concomitant BOP. In accordance with the manufacturer's recommendations, Elyzol® Dental Gel was applied for a second time 7 days later. In addition to the clinical evaluation, subgingival microbiological samples were collected prior to treatment (i.e. Week 2) and at Weeks 4 and 18. Analysis of variance/covariance was used to evaluate changes from baseline to Week 18 for the clinical parameters. Results: Between the baseline and 18-week examinations, subjects treated with Atridox showed a significantly greater gain in mean PAL of 0.33 mm ± 0.09 (SD) than subjects treated with Elyzol® Dental Gel [0.03 mm ± 0.09 (SD)] (p = 0.03). However, the gain in PAL of 0.16 mm ± 0.10 (SD) found after PerioChip® application did not differ significantly from that obtained following the application of Atridox™ (p = 0.27). Of the sites treated with Atridox™, 42% gained ≥1 mm PAL and 9% ≥ 2 mm PAL as opposed to the sites treated with Elyzol® Dental Gel, in which 34% gained ≥ 1 mm PAL and 8% gained ≥ 2 mm PAL. Of the sites treated with PerioChip®, 36% gained ≥ 1 mm and 6% gained ≥ 2 mm PAL following a completed initial periodontal therapy. Conclusions: The application of the three biodegradable sustained release devices tested following initial periodontal therapy resulted in a statistically significant gain in mean PAL for Atridox™ and a significant reduction in PPD for all three devices during the study period. Furthermore, when sites treated with Atridox™ were compared with sites treated with Elyzol®, a significant difference in mean PAL gain (0.3 mm) was observed. © Blackwell Munksgaard, 2002. |
Persistent Identifier | http://hdl.handle.net/10722/154199 |
ISSN | 2023 Impact Factor: 5.8 2023 SCImago Journal Rankings: 2.249 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Salvi, GE | en_US |
dc.contributor.author | Mombelli, A | en_US |
dc.contributor.author | Mayfield, L | en_US |
dc.contributor.author | Rutar, A | en_US |
dc.contributor.author | Suvan, J | en_US |
dc.contributor.author | Garrett, S | en_US |
dc.contributor.author | Lang, NP | en_US |
dc.date.accessioned | 2012-08-08T08:23:50Z | - |
dc.date.available | 2012-08-08T08:23:50Z | - |
dc.date.issued | 2002 | en_US |
dc.identifier.citation | Journal Of Clinical Periodontology, 2002, v. 29 n. 6, p. 540-550 | en_US |
dc.identifier.issn | 0303-6979 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/154199 | - |
dc.description.abstract | Aim: The aim of this single-blind, randomized, parallel-designed clinical trial (RCT) was to evaluate the clinical and microbiological effects of three sustained-release biodegradable polymers delivered into periodontal pockets following initial periodontal therapy. Methods: Forty-seven patients (28 females and 19 males) with a mean age of 51 years (range 29-71) underwent a periodontal examination at baseline (i.e. Week 0) and after 18 weeks. This included the assessment of the Plaque Index (PlI), Bleeding on Probing (BOP), Pocket Probing Depths (PPD) and Probing Attachment Levels (PAL) at six sites per tooth. Two to 4 months prior to baseline, all subjects had received initial periodontal therapy including motivation, instruction in oral hygiene practices and full-mouth scaling and root planing. At the treatment appointment (i.e. Week 2), the patients were randomly assigned to receive either Atridox™, Elyzol® Dental Gel or PerioChip® at all residual periodontal pockets with a probing depth ≥ 5 mm and concomitant BOP. In accordance with the manufacturer's recommendations, Elyzol® Dental Gel was applied for a second time 7 days later. In addition to the clinical evaluation, subgingival microbiological samples were collected prior to treatment (i.e. Week 2) and at Weeks 4 and 18. Analysis of variance/covariance was used to evaluate changes from baseline to Week 18 for the clinical parameters. Results: Between the baseline and 18-week examinations, subjects treated with Atridox showed a significantly greater gain in mean PAL of 0.33 mm ± 0.09 (SD) than subjects treated with Elyzol® Dental Gel [0.03 mm ± 0.09 (SD)] (p = 0.03). However, the gain in PAL of 0.16 mm ± 0.10 (SD) found after PerioChip® application did not differ significantly from that obtained following the application of Atridox™ (p = 0.27). Of the sites treated with Atridox™, 42% gained ≥1 mm PAL and 9% ≥ 2 mm PAL as opposed to the sites treated with Elyzol® Dental Gel, in which 34% gained ≥ 1 mm PAL and 8% gained ≥ 2 mm PAL. Of the sites treated with PerioChip®, 36% gained ≥ 1 mm and 6% gained ≥ 2 mm PAL following a completed initial periodontal therapy. Conclusions: The application of the three biodegradable sustained release devices tested following initial periodontal therapy resulted in a statistically significant gain in mean PAL for Atridox™ and a significant reduction in PPD for all three devices during the study period. Furthermore, when sites treated with Atridox™ were compared with sites treated with Elyzol®, a significant difference in mean PAL gain (0.3 mm) was observed. © Blackwell Munksgaard, 2002. | en_US |
dc.language | eng | en_US |
dc.publisher | Blackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CPE | en_US |
dc.relation.ispartof | Journal of Clinical Periodontology | en_US |
dc.subject | Biodegradable drug delivery systems | - |
dc.subject | Microbiological effects | - |
dc.subject | Periodontal disease | - |
dc.subject | Periodontal therapy | - |
dc.subject | Randomized clinical trial (RCT) | - |
dc.subject.mesh | Actinobacillus Actinomycetemcomitans - Growth & Development | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Analysis Of Variance | en_US |
dc.subject.mesh | Anti-Bacterial Agents - Administration & Dosage - Therapeutic Use | en_US |
dc.subject.mesh | Anti-Infective Agents, Local - Administration & Dosage - Therapeutic Use | en_US |
dc.subject.mesh | Biodegradation, Environmental | en_US |
dc.subject.mesh | Chlorhexidine - Administration & Dosage - Analogs & Derivatives - Therapeutic Use | en_US |
dc.subject.mesh | Colony Count, Microbial | en_US |
dc.subject.mesh | Delayed-Action Preparations | en_US |
dc.subject.mesh | Dental Plaque Index | en_US |
dc.subject.mesh | Doxycycline - Administration & Dosage - Analogs & Derivatives - Therapeutic Use | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Follow-Up Studies | en_US |
dc.subject.mesh | Fusobacterium - Growth & Development | en_US |
dc.subject.mesh | Gingival Hemorrhage - Drug Therapy | en_US |
dc.subject.mesh | Glycerides - Administration & Dosage - Therapeutic Use | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Metronidazole - Administration & Dosage - Analogs & Derivatives - Therapeutic Use | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Periodontal Attachment Loss - Drug Therapy | en_US |
dc.subject.mesh | Periodontal Pocket - Drug Therapy - Microbiology | en_US |
dc.subject.mesh | Periodontitis - Drug Therapy - Microbiology | en_US |
dc.subject.mesh | Porphyromonas - Growth & Development | en_US |
dc.subject.mesh | Prevotella - Growth & Development | en_US |
dc.subject.mesh | Sesame Oil - Administration & Dosage - Therapeutic Use | en_US |
dc.subject.mesh | Single-Blind Method | en_US |
dc.subject.mesh | Treatment Outcome | en_US |
dc.title | Local antimicrobial therapy after initial periodontal treatment: A randomized clinical trial comparing three biodegradable sustained release polymers | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lang, NP:nplang@hkucc.hku.hk | en_US |
dc.identifier.authority | Lang, NP=rp00031 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1034/j.1600-051X.2002.290611.x | en_US |
dc.identifier.pmid | 12296782 | - |
dc.identifier.scopus | eid_2-s2.0-0036598367 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0036598367&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 29 | en_US |
dc.identifier.issue | 6 | en_US |
dc.identifier.spage | 540 | en_US |
dc.identifier.epage | 550 | en_US |
dc.identifier.isi | WOS:000178184000011 | - |
dc.publisher.place | Denmark | en_US |
dc.identifier.scopusauthorid | Salvi, GE=35600695300 | en_US |
dc.identifier.scopusauthorid | Mombelli, A=7006180872 | en_US |
dc.identifier.scopusauthorid | Mayfield, L=7004160753 | en_US |
dc.identifier.scopusauthorid | Rutar, A=6602283506 | en_US |
dc.identifier.scopusauthorid | Suvan, J=19637686000 | en_US |
dc.identifier.scopusauthorid | Garrett, S=7102507165 | en_US |
dc.identifier.scopusauthorid | Lang, NP=7201577367 | en_US |
dc.identifier.issnl | 0303-6979 | - |